Filing Flows › Abbott Laboratories (ABT) › Q2 2026 › vs Q1 2026
Abbott Laboratories (ABT) Q2 2026 vs Q1 2026 (quarter over quarter)
Abbott Laboratories's revenue rose $1.4B (+13%) from $11.2B in Q1 2026 to $12.6B in Q2 2026. Operating margin 13.4% against 12.0% (+1.4 pts).
Abbott Laboratories, Q2 2026: revenue $12.6B (+13% year over year), operating margin 13.4%, net earnings $928M, operating cash flow $2.5B. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 13.4% | 12.0% | +1.4 pts |
| Net margin | 7.4% | 9.6% | -2.3 pts |
| Free cash flow margin | 15.8% | 8.2% | +7.6 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $12.6B | $11.2B | $1.4B | +13% |
| Operating profit | $1.7B | $1.3B | $348M | +26% |
| Costs & expenses | $10.9B | $9.8B | $1.1B | +11% |
| Pre-tax earnings | $1.5B | $1.4B | $75.0M | +5% |
| Other expense, net | $169M | −$104M | $273M | — |
| Cost of revenue | $5.3B | $4.9B | $435M | +9% |
| Research & development | $892M | $767M | $125M | +16% |
| SG&A | $4.0B | $3.7B | $285M | +8% |
| Other operating costs | $658M | $422M | $236M | +56% |
| Net earnings | $928M | $1.1B | −$149M | -14% |
| Income tax | $596M | $372M | $224M | +60% |
| Depreciation & amortization | $1.1B | $803M | $257M | +32% |
| Share-based compensation | $168M | $317M | −$149M | -47% |
| Working capital & other | $332M | −$882M | $1.2B | — |
| Operating cash flow | $2.5B | $1.3B | $1.2B | +89% |
| Free cash flow (OCF − capex) | $2.0B | $916M | $1.1B | +117% |
| Capital expenditures | $497M | $399M | $98.0M | +25% |
Questions
How much did Abbott Laboratories's revenue grow quarter over quarter in Q2 2026?
Abbott Laboratories's revenue rose $1.4B (+13%) from $11.2B in Q1 2026 to $12.6B in Q2 2026. Operating margin 13.4% against 12.0% (+1.4 pts).